Atezolizumab

Excerpt

Atezolizumab is a humanized IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1). Atezolizumab has received FDA approval for multiple neoplastic conditions and may be administered as monotherapy or in combination with chemotherapy. Indications include locally advanced or metastatic urothelial carcinoma, metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic triple-negative breast cancer, and unresectable or metastatic hepatocellular carcinoma.